Turkish Journal of Nephrology
Case Report

Two Different Presentation of C3 Glomerulonephritis Treated with Eculizumab: Two Cases and Brief Overview

1.

Department of Nephrology, Necmettin Erbakan University, Meram School of Medicine, Konya, Türkiye

2.

Department of Nephrology, Ömer Halisdemir University, Training and Research Hospital, Niğde, Türkiye

Turkish J Nephrol 2023; 32: 86-89
DOI: 10.5152/turkjnephrol.2023.21141125
Read: 751 Downloads: 288 Published: 18 May 2022

C3 glomerulopathy (C3 GP) is a newly-defined glomerular disease dominated by C3 complement storage and uncertain C1, C4 and immunoglobin accumulations. Hereditary mutations associated with CFH causing hyperactivation of the alternative complement pathway were identified. Most mutations associated with C3 GP are associated with the N-terminal end. Whether mutations are pathogenic or not will direct diagnosis and treatment. We present two cases, one 61-years-old and one 24-years-old attending our clinic at different times with hematuria, proteinuria, edema and kidney failure. Both patients had C3 glomerulopathy diagnosed based on the results of kidney biopsy and were treated with eculizumab. Both cases had CFH-associated mutations.

Cite this article as: Öztürk Y, Özer H, Baloğlu İ, Türkmen K. Two different presentation of C3 glomerulonephritis treated with eculizumab: Two cases and brief overview. Turk J Nephrol. 2023;32(1):86-89.

Files
EISSN 2667-4440